From ovarian aging to healthcare access, the finalists reflect a longevity sector that is broadening in both scope and ambition.
The Longevity Show has announced the five finalists selected to compete in its inaugural Pitch Competition, with companies spanning therapeutics, nutrition, digital health and healthcare delivery set to take the stage in London next month.
Chosen from a shortlist of 30 companies, the finalists are Anyo Labs, Enbiosis Biotechnology, OvartiX, The Protein Brewery and Zuri Health. The competition forms part of The Longevity Show 2026, which is set to bring together innovators, investors, clinicians, researchers and consumers working across the healthy longevity ecosystem.
The finalists represent a geographically diverse cohort, with companies headquartered in Sweden, the United Kingdom, the Netherlands and Kenya. Collectively, they illustrate the increasingly broad range of approaches now emerging under the longevity umbrella – from AI-enabled drug discovery and women’s health therapeutics to microbiome-informed nutrition and healthcare access in underserved populations.
Longevity.Technology: What is interesting about this final five is not simply that they are promising companies; promising companies, after all, are what pitch competitions are supposed to produce, otherwise we would all be politely clapping our way through a very long afternoon. What stands out is that they map something rather more important: the widening definition of longevity itself. Here are AI-enabled therapeutics targeting inflammaging, ovarian biology being treated as core healthspan science rather than a specialist women’s health footnote, microbiome-informed precision nutrition, fermentation-derived protein with cellular-renewal relevance and healthcare delivery infrastructure built for markets too often excluded from the longevity conversation. Taken together, they suggest a sector moving beyond the search for a single intervention and toward an operating system for aging well – one that spans molecules, models, food, care pathways and access. That matters economically as much as scientifically; if longevity is to help societies absorb the pressures of demographic change, it cannot remain a boutique promise for the already optimized.
The future of healthspan will be built at the points of convergence – between biology and computation, nutrition and prevention, clinics and community, developed and emerging markets – and this cohort suggests that the field is beginning to understand that the real prize is not just adding years, but building the infrastructure to make those years healthier, more equitable and rather less expensive to endure.
A difficult choice
According to organizers, selecting the final five proved challenging given both the quality and diversity of applications received.
“It has been incredibly inspiring to engage with and learn from such a diverse and forward thinking group of companies,” Saoirse O’Shea, Content Lead at The Longevity Show told us. “The depth of innovation across this space is remarkable and it has been a privilege to meet founders and teams who are genuinely reshaping how we think about health, prevention and longevity. Distilling such a strong and varied applicant pool down to just a handful of finalists has been no easy task. The top five selected are truly exceptional and we are really looking forward to seeing them bring their ideas to life on our stage next month. It is not to be missed!”
Anyo Labs tackles inflammaging
For Swedish company Anyo Labs, longevity begins with discovery itself. The company has developed a patented AI-powered drug discovery platform that screens potential therapeutics at 100x the speed of conventional approaches, securing the top ranking in the 2025 CACHE benchmark and boasting a 26% experimental hit rate. Its lead program targets NLRP3, an inflammatory pathway central to inflammaging and implicated in neurodegenerative, cardiovascular, and metabolic decline. By accelerating the path to brain-penetrant, oral therapies, Anyo is looking to cut down the timeline from biological discovery to actual healthspan intervention.
OvartiX focuses on ovarian aging
Cambridge-based OvartiX is approaching longevity through a distinctly female lens, pioneering therapeutics for ovarian biology and aging. Combining human multi-omics, machine learning and proprietary 2D and 3D engineered ovarian models, the company is building a drug discovery platform purpose-built for female physiology. Its lead asset, OVX001, is a first-in-class treatment designed to prevent medically induced menopause and preserve endocrine function in cancer patients – an indication with broader implications for cytoprotection, fertility expansion, and systemic healthy aging.
Enbiosis turns the microbiome into a platform
The gut microbiome remains one of longevity science’s most intriguing frontiers, and Enbiosis Biotechnology is seeking to make it programmable. Using a genome-scale metabolic simulation engine and digital twin technology, the UK-based company designs condition-specific, precision nutraceutical formulations using food-grade, EFSA- and FDA GRAS-compliant ingredients. By avoiding a traditional drug regulatory pathway, Enbiosis accelerates its time-to-market; its flagship dry eye formulation already demonstrated a 60.7% improvement in tear production in a registered clinical trial. Through a B2B licensing model, they aim to deploy a pipeline spanning over 100 health conditions across metabolic, neurological, and immune health.
The Protein Brewery rethinks longevity nutrition
Nutrition takes center stage at Dutch ingredient innovator The Protein Brewery. The company’s fermentation-derived, FSSC 22000-certified whole-food mycelium protein, Fermotein, naturally delivers spermidine at 7–10x the concentration found in wheat germ, alongside 50% complete protein and 30% prebiotic fiber. With preclinical studies showing it elevates GLP-1, induces short-chain fatty acid responses and increases gut microbial diversity, the ingredient links directly to autophagy pathways central to healthspan research. Following a positive EFSA safety opinion, the company expects EU authorization this summer, with 100 MT already committed for 2026.
Zuri Health expands access
Not every longevity challenge begins in a laboratory. Operating across nine African markets and serving more than six million users, Kenyan healthtech company Zuri Health is focused on expanding healthcare access through a mix of digital platforms, insurance-linked care, community outreach and continuous clinical infrastructure. Accessible via standard apps, WhatsApp, SMS, AI tools and physical “Zuri Express” mobile clinics, the model targets an often-overlooked reality: preventive care can only impact healthspan if the infrastructure exists to deliver early screening and chronic disease management to underserved populations.
A stage for the sector
The five finalists will present their businesses at The Longevity Show, where they will have the opportunity to showcase their technologies before an audience of investors, industry leaders, researchers and healthcare stakeholders.
Their approaches differ considerably; their target markets differ too. Yet viewed together, they offer a useful snapshot of a field in transition. Longevity is no longer confined to laboratories, supplement shelves or venture capital presentations. It is becoming a meeting point – sometimes an uneasy one – between biology and technology, prevention and treatment, innovation and access. The conversations that emerge on stage may prove every bit as interesting as the competition itself.
The Longevity Show opens its doors on 26–27 June 2026 at Tobacco Dock, London. Tickets for all tiers are now available at www.longevityshow.com.
